MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication but improved irritability in teenagers.
MapLight Therapeutics is holding to hope that there’s a path forward for its autism drug despite the program flunking a mid-stage study.
The biotech’s treatment …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802
Definium LSD therapy helped patients with major depression in late-stage trial
FDA Reverses Course on Neuro Drugs; Omega-3s and Dementia; Brain Death Test Lawsuit
LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors
Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection
New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
News and commentary from the world of neurology and neuroscience
The agency expanded use of an old drug as a treatment for some people with autism. The endorsement sent some customers scrambling…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
